The efficiency of bazedoxifene, another endocrine therapy agent (estrogen-receptor agonist/antagonist), was evaluated in endocrine-resistant HR+ breast cancer patients during clinical trial NCT02448771 (Table 3). The gene discussed is ESR1; the disease is breast cancer.